MARLBOROUGH, Mass.,
Jan. 17, 2018 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a
clinical-stage company developing a new class of RNAi-based
therapeutics today announced that it will give an oral presentation
highlighting the company's proprietary therapeutic platform at the
Immuno-Oncology Frontiers World conference. This exclusive
Immuno-oncology (I-O) partnering event provides direct access to
decision makers and KOL's working towards the next oncology
blockbuster. Also, this is the only I-O event co-located with the
leading Cell and Gene Therapy global meeting; providing access to
the most commercially advanced technical expertise specifically for
cellular immunotherapies. The conference will take place
January 22-25, 2018 at the Hyatt
Regency in Miami, Florida.
Title: Targeting Immune
Checkpoints Using Self-Delivering RNAi (sd-rxRNA®) Technology
Session: Stream 2- Emerging Science: Reprogramming the Tumor
Microenvironment – Conquering Immune Suppressive Molecular Pathways
Date and Time: Tuesday, January
23, 2018, at 11:50 am ET
Presenter: James Cardia, Ph.D., Director of Business
Development and Intellectual Property
The presentation will be available on the Company's website
approximately 1 hour after the presentation at
www.rxipharma.com.
Logo -
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
About RXi's self-delivering RNAi (sd-rxRNA) technology
platform
sd-rxRNA, RXi's proprietary self-delivering RNAi platform, is a
single chemically modified compound with delivery and therapeutic
properties built directly into the compound itself. The compound is
asymmetrical with a phosphorothioate backbone and contains chemical
modifications that provide for efficient cellular uptake and gene
silencing. These compounds are potent, stable and specific, and
demonstrated to be safe and active in a clinical setting.
RXi's novel sd-rxRNA technology differs from natural and most
synthetic RNA interference (RNAi) molecules in that they are
chemically modified to allow for efficient internalization of the
compounds by cells and silencing of the targeted genes.
Importantly, unlike other naked siRNA compounds, delivery of
sd-rxRNAs are not limited to a specific cell type. For local
delivery and ex vivo cell-based therapeutic applications,
our compounds do not require delivery vehicles. This is a major
advantage since delivery vehicles can have related toxicity that
affects cell viability. sd-rxRNA has demonstrated nearly 100
percent transfection efficiency with high cell viability in
numerous cell types.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform, including self-delivering RNA
(sd-rxRNA®) compounds, that has the potential to highly selectively
block the expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology, and cell-based
immunotherapy. RXi's extensive patent portfolio provides for
multiple product and business development opportunities across a
broad spectrum of therapeutic areas, and we actively pursue
research collaborations, partnering and out-licensing opportunities
with academia and pharmaceutical companies. For additional
information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™,
RXI-762, RXI-804 and our other product candidates (collectively
"our product candidates"); the future success of our clinical
trials with our product candidates; the timing for the commencement
and completion of clinical trials; our ability to enter into
strategic partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-immuno-oncology-frontiers-world-conference-300583252.html
SOURCE RXi Pharmaceuticals Corporation